|
Post by centralcoastinvestor on Nov 27, 2018 9:17:47 GMT -5
|
|
|
Post by boca1girl on Nov 27, 2018 9:23:11 GMT -5
Glad to see we have a female board member with relevant experience.
|
|
|
Post by dreamontrader on Nov 27, 2018 9:27:15 GMT -5
This will meet CA new requirement to have at least 1 female board member.
|
|
|
Post by goyocafe on Nov 27, 2018 9:27:41 GMT -5
|
|
|
Post by derek2 on Nov 27, 2018 9:32:43 GMT -5
She sounds like a strong addition, especially with the experience of moving towards abbreviated NDAs for inhaled reformulations - exactly what MNKD needs to exploit their inhalation platform.
|
|
|
Post by uvula on Nov 27, 2018 9:40:48 GMT -5
It is good to have a preselected potential backup CEO for MNKD on the MNKD board. I'm not suggesting anything negative by this.
I'm surprised the UT CEO wasn't added to the board instead of this lady.
|
|
|
Post by porkini on Nov 27, 2018 10:38:09 GMT -5
|
|
|
Post by porkini on Nov 27, 2018 11:07:17 GMT -5
Hmm, okay, I'll try to finish that for you. How'd I do?
|
|
|
Post by mnkdfann on Nov 27, 2018 11:11:23 GMT -5
She should bring relevant experience. Impopharma, though, isn't a particularly large company from what I can find online. "Impopharma Inc. is a Toronto, Canada-based developer of pharmaceutical products and complex formulations focused on inhalation pharmaceutical products (solution and suspension sprays, pMDI and DPI). It was founded in 1996 as a CRO by Hanna Piskorz and Harold Wulffhart in a single office enterprise of ~150 ft², that has grown over a span of 20 years with a footprint of ~15,000 ft² comprised of laboratory, small pilot manufacturing, document storage, sample storage and office space that houses a staff of over 40 employees operating within an FDA and Health inspected QMS." Not being negative, though. She's a decent choice, and has prior experience with larger companies than Impopharma.
|
|
|
Post by goyocafe on Nov 27, 2018 11:18:11 GMT -5
Hmm, okay, I'll try to finish that for you. How'd I do? I'll bake you a brownie.
|
|
|
Post by porkini on Nov 27, 2018 11:21:28 GMT -5
She should bring relevant experience. Impopharma, though, isn't a particularly large company from what I can find online. "Impopharma Inc. is a Toronto, Canada-based developer of pharmaceutical products and complex formulations focused on inhalation pharmaceutical products (solution and suspension sprays, pMDI and DPI). It was founded in 1996 as a CRO by Hanna Piskorz and Harold Wulffhart in a single office enterprise of ~150 ft², that has grown over a span of 20 years with a footprint of ~15,000 ft² comprised of laboratory, small pilot manufacturing, document storage, sample storage and office space that houses a staff of over 40 employees operating within an FDA and Health inspected QMS." Not being negative, though. She's a decent choice, and has prior experience with larger companies than Impopharma. Hmm, I didn't see that info in the news release. Anyway though, maybe it is the growth aspect if that information is indeed true, "~150 ft², that has grown over a span of 20 years with a footprint of ~15,000 ft²" or the pilot manufacturing or storage of documents and samples or the FDA and Health inspected QMS - who knows, maybe it is all of them?
|
|
|
Post by mnkdfann on Nov 27, 2018 11:24:47 GMT -5
She should bring relevant experience. Impopharma, though, isn't a particularly large company from what I can find online. "Impopharma Inc. is a Toronto, Canada-based developer of pharmaceutical products and complex formulations focused on inhalation pharmaceutical products (solution and suspension sprays, pMDI and DPI). It was founded in 1996 as a CRO by Hanna Piskorz and Harold Wulffhart in a single office enterprise of ~150 ft², that has grown over a span of 20 years with a footprint of ~15,000 ft² comprised of laboratory, small pilot manufacturing, document storage, sample storage and office space that houses a staff of over 40 employees operating within an FDA and Health inspected QMS." Not being negative, though. She's a decent choice, and has prior experience with larger companies than Impopharma. Hmm, I didn't see that info in the news release. Anyway though, maybe it is the growth aspect if that information is indeed true, "~150 ft², that has grown over a span of 20 years with a footprint of ~15,000 ft²" or the pilot manufacturing or storage of documents and samples or the FDA and Health inspected QMS - who knows, maybe it is all of them? It wasn't. I just googled for the company name listed in the PR and found its site. www.impopharma.com/about
|
|
|
Post by Clement on Nov 27, 2018 11:35:33 GMT -5
She's intelligent and savvy with good experience in both large and small pharma. I think a potential institutional investor would put a check mark in the "pro" column when looking at pros and cons of MNKD.
|
|
|
Post by letitride on Nov 27, 2018 20:53:15 GMT -5
Christine looks like a great addition to the board appears to have the right stuff. Another good fit at the right time. Lets Go!
|
|
|
Post by longliner on Nov 27, 2018 21:14:03 GMT -5
I see the addition to our BOD of a professional, that was CEO of a Canadien company, that produced inhaled Pharmaceutical products (thanks Mannkind Fan) (I continue to question your motives) , as a positive for the BOD. Although, I am reasonably obtuse.
|
|